Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

$54.72 -4.94 (-8.28%)

(As of 11/15/2024 ET)

Crinetics Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
1

Buy
10

Based on 11 Wall Street analysts who have issued ratings for Crinetics Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a hold rating, and 10 have given a buy rating for CRNX.

Consensus Price Target

$70.18
28.26% Upside

According to the 11 analysts' twelve-month price targets for Crinetics Pharmaceuticals, the average price target is $70.18. The highest price target for CRNX is $97.00, while the lowest price target for CRNX is $35.00. The average price target represents a forecasted upside of 28.26% from the current price of $54.72.

Get the Latest News and Ratings for CRNX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors.

CRNX Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$70.18	$68.55	$64.75	$45.71
Forecasted Upside	28.26% Upside	16.46% Upside	25.44% Upside	61.31% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Financial Prophecy (Ad)

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

CRNX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Crinetics Pharmaceuticals Stock vs. The Competition

Type	Crinetics Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.26% Upside	28,186.82% Upside	9.93% Upside
News Sentiment Rating	Neutral News See Recent CRNX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$70.00 ➝ $74.00	+19.35%
11/13/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$69.00 ➝ $81.00	+35.63%
9/27/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$80.00 ➝ $80.00	+58.51%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00	+67.54%
8/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$74.00 ➝ $73.00	+51.42%
7/9/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$47.00 ➝ $54.00	+15.16%
Get the Latest News and Ratings for CRNX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
7/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$97.00 ➝ $97.00	+110.92%
5/23/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$52.00 ➝ $62.00	+27.78%
5/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$50.00 ➝ $70.00	+41.84%
3/20/2024	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$52.00 ➝ $56.00	+23.95%
12/21/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$35.00	+1.48%
9/11/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$41.00 ➝ $48.00	+200.56%
3/27/2023	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Jubinville Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 08:48 PM ET.

CRNX Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Crinetics Pharmaceuticals is $70.18, with a high forecast of $97.00 and a low forecast of $35.00.
: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There is currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRNX shares.
: According to analysts, Crinetics Pharmaceuticals's stock has a predicted upside of 28.26% based on their 12-month stock forecasts.
: Crinetics Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, Citigroup, HC Wainwright, and JMP Securities in the past 90 days.
: Analysts like Crinetics Pharmaceuticals more than other "medical" companies. The consensus rating score for Crinetics Pharmaceuticals is 2.91 while the average consensus rating score for "medical" companies is 2.80. Learn more on how CRNX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[Urgent] Starlink Set For The Largest IPO In History? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

This page (NASDAQ:CRNX) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target